NeuroSearch to make a presentation at the 10th Annual Bear Stearns Healthcare Conference

Investor News                                                                   


NeuroSearch to make a presentation at the 10th Annual Bear Stearns Healthcare   
Conference                                                                      

NeuroSearch will make a presentation at the 10th Annual Bear Stearns Healthcare 
Conference to be held on 13 March 2008 in London.                               


NeuroSearch's presentation is scheduled for                                     

Thursday 13 March 2008 at 9.30-10.45 local time                                 

and will be held by CEO Flemming Pedersen.                                      


A powerpoint version of the presentation will be available via                  
www.neurosearch.com just after the presentation has been held at the conference.




Contact person:                                                                 

Hanne Leth Hillman, Vice President, Director of IR & Corporate Communications,  
telephone: +45 4017 5103                                                        




NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX
Nordic Exchange Copenhagen A/S. Our core business covers the development of     
novel drugs, based on a broad and well-established drug discovery platform      
focusing on ion channels and CNS disorders. A substantial part of the company's 
activities are partner financed through a broad alliance with GlaxoSmithKline   
(GSK) and collaborations with among others Abbott and Astellas. The drug        
pipeline comprises 12 clinical (Phase I-III) development programmes: ACR16 in   
Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase  
III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in     
partnership with GSK, ABT-894 in ADHD (Phase II) and pain (Phase II) in         
partnership with Abbott, ACR16 in schizophrenia (Phase I) in partnership with   
Astellas, ACR325 in bipolar disorder/Parkinson's disease (Phase I), ABT-107 as  
well as ABT-560 for the treatment of various CNS diseases - both (Phase I) in   
collaboration with Abbott, NSD-644 in pain a.o. (Phase I) in partnership with   
GSK and ACR343 in Parkinson's disease (Phase I). In addition, NeuroSearch has a 
broad portfolio of preclinical drug candidates and holds equity interests in    
several biotech companies.